Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,168 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunodeficiency Diseases Clear all
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

NCT01433289
View directory record Official record
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 2Phase 3 Interventional

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, HYQVIA
Biological
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

NCT00002126
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Filgrastim
Drug
Lead sponsor
Amgen
Industry
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 15, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

NCT00006440
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Inflammation and Cognition

NCT03384784
View directory record Official record
Conditions
HIV Associated Cognitive Motor Complex
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

NCT00099684
View directory record Official record
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 15, 2026, 10:47 AM EDT
Withdrawn No phase listed Observational

Food Assistance, Diabetes, and HIV

NCT04045184
View directory record Official record
Conditions
Diabetes, HIV/AIDS, FOOD SECURITY
Interventions
Food assistance
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIV Prevention Intervention for Young Transgender Women

NCT01575938
View directory record Official record
Conditions
Sexual Transmission of Infection
Interventions
HIV prevention intervention, Diet and Nutrition
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
16 Years to 29 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

NCT01231516
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572, Raltegravir, GSK1349572 Placebo, Raltegravir Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

NCT00102089
View directory record Official record
Conditions
Healthy, HIV Infections
Interventions
VRC-HIVADV014-00-VP booster, VRC-HIVADV014-00-VP
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Retention in HIV Care for Hispanic Immigrants

NCT03484117
View directory record Official record
Conditions
HIV/AIDS
Interventions
Community Health Worker
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

NCT03547245
View directory record Official record
Conditions
HIV/AIDS
Interventions
eOD-GT8 60mer + AS01B/ DPBS sucrose/IM, DPBS Sucrose
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

NCT00006279
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

NCT00071097
View directory record Official record
Conditions
HIV Infections
Interventions
TMC114/rtv
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Preliminary Study of Safety and Efficacy of Policosanol

NCT00312923
View directory record Official record
Conditions
Dyslipidemia, HIV Infections
Interventions
Policosanol, Placebo
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 15, 2026, 10:47 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

NCT05001373
View directory record Official record
Conditions
Hiv
Interventions
Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 15, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People

NCT00919724
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project ICARE: Intervening for Community Awareness, Respect, & Empowerment

NCT00712088
View directory record Official record
Conditions
HIV Infections
Interventions
Project ICARE, HCT
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Sep 15, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

NCT06103370
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders, Addiction, Opioid Use, Drug Use, Intravenous Drug Usage
Interventions
Peer-educator-based network
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

NCT00032669
View directory record Official record
Conditions
HIV Infections
Interventions
HAART
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Treatment of Hepatitis C in Hemophilic Patients With HIV

NCT00055341
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Hemophilia
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 15, 2026, 10:47 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

NCT03505060
View directory record Official record
Conditions
HIV Infections
Interventions
DNA CON-S env, IHV01, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 15, 2026, 10:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 15, 2026, 10:47 AM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 15, 2026, 10:47 AM EDT